Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT06982820 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).

Conditions Studied

Interventions

  • DEVICE Prism Training

Study Locations (3)

Rhode Island

  • Butler Hospital — Providence

Texas

  • Houston Center For Advanced Psychiatric Treatment — Houston

Other

  • Sheba Medical Center — Ramat Gan

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2025-06-25
Est. Completion 2027-08-30
Phase NA

Sponsor

GrayMatters Health

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06982820

The ClinicalTrials.gov registry entry for NCT06982820 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GrayMatters Health, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention — of which Prism Training is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06982820 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Rhode Island, Texas, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06982820 about?

NCT06982820 is a clinical study titled "Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia". The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of ne...

What is the current status of trial NCT06982820?

This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2025-06-25. Estimated completion is 2027-08-30.

What conditions does trial NCT06982820 study?

This clinical trial studies the following conditions: Depressive Disorder, Major. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06982820?

The interventions under investigation include: Prism Training (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06982820?

This trial is sponsored by GrayMatters Health, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06982820 being conducted?

This trial has 3 study locations across Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial